 | | Vol. 15.25 – 6 July, 2023 |
| |
|
|
| This Phase I dose-escalation study investigated placenta-derived MSCs in nine CLI patients who were enrolled into each of the two dosage groups, delivered intramuscularly twice, two months apart.
[Stem Cell Research & Therapy] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Human MSCs were derived from bone marrow, adipose tissue, and umbilical cord. In vitro immunomodulatory potential was determined by co-culture experiments between human MSCs and immune cells implicated in acute graft-versus-host disease progression.
[Stem Cell Research & Therapy] |
|
|
|
| Researchers examined the effect of interleukin-1β stimulated human umbilical cord MSCs on immunoregulation of M1 and M2 macrophages in vitro and in the rheumatoid arthritis mouse model.
[Scientific Reports] |
|
|
|
| Exposure to valproic acid was found to dose-dependently influence syncytialization-associated genes in differentiated human placental choriocarcinoma BeWo cells.
[Toxicology And Applied Pharmacology] |
|
|
|
| Investigators used nanovibration to induce the differentiation of MSCs toward the tenogenic fate solely by the use of nanovibration, and without the need for growth factors or complex scaffolds.
[In Vitro Cellular & Developmental Biology – Animal] |
|
|
|
| To better understand the distinctions between umbilical cord-derived MSCs and MSCs derived from other tissues, researchers conducted a transcriptome analysis of MSCs obtained from umbilical cord and three other tissues
[Cellular Reprogramming] |
|  |
|
|
|
| The authors provide a summary of the current understanding on how G protein-coupled estrogen receptor stimulation regulates some of the features of normal pregnancy, and a potential link between its signaling network and uteroplacental dysfunction in preeclampsia.
[Reproductive Biology And Endocrinology] |
|
|
|
|
| California-based regenerative therapeutics company StemCyte announced it has signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood.
[StemCyte (PR Newswire)] |
|
|
|
|
| August 3, 2023
New York, New York, United States |
|
|
|
|
|
| | Duke University’s Marcus Center for Cellular Cures – Durham, North Carolina, United States |
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | The University of California San Francisco – San Francisco, California, United States |
|
|
|
| | The Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | University of Edinburgh – Edinburgh, Scotland, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
